Research progress on Bumetanide treatment for autism spectrum disorder in children

VernacularTitle:布美他尼治疗儿童孤独症谱系障碍的研究进展
Author: Cailing DUAN ¹ ; Lanmin GUO ; Xinyu ZHOU
Author Information

1. 佳木斯大学康复医学院，佳木斯　154000
Keywords: Child; Autism spectrum disorder; Bumetanide; γ-aminobutyric acid
From: Chinese Journal of Applied Clinical Pediatrics 2024;39(8):625-628
CountryChina
Language:Chinese
Abstract: Autism spectrum disorder(ASD) comprises neurodevelopmental disorders characterized by core symptoms of social communication disorders, restricted interests, and repetitive behaviors.With increasing incidence year by year, ASD may persist throughout life.The current clinical treatment is mainly behavioral intervention, occasionally supplemented with medication to treat the accompanying symptoms, such as irritability, paresthesia, sleep disorders, and gastrointestinal diseases, but there is still a lack of specific drugs targeting the core symptoms of ASD.Bumetanide, an U. S.Food and Drug Administration-approved diuretic, has been proposed as a candidate to treat the core symptoms of ASD.This article mainly reviews the latest research progress on Bumetanide treatment of core symptoms in children with ASD, providing a theoretical basis for the research and application of Bumetanide.